Matching articles for "Belbuca"
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • December 12, 2022; (Issue 1665)
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • April 9, 2018; (Issue 1544)
Use of nonopioid drugs for pain was reviewed in a
previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations...
Use of nonopioid drugs for pain was reviewed in a
previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations of full opioid agonists should generally be used for acute pain that is severe enough to require treatment with an opioid. Use of extended-release or long-acting opioid formulations initially and treatment durations >1 week have been associated with an increased risk of unintended long-term use.
Buprenorphine Buccal Film (Belbuca) for Chronic Pain
The Medical Letter on Drugs and Therapeutics • April 11, 2016; (Issue 1492)
Belbuca (Endo), a buccal formulation of the partial
opioid agonist buprenorphine, has been approved by the
FDA for management of pain severe enough to require
daily, around-the-clock, long-term opioid...
Belbuca (Endo), a buccal formulation of the partial
opioid agonist buprenorphine, has been approved by the
FDA for management of pain severe enough to require
daily, around-the-clock, long-term opioid treatment.
Buprenorphine is also available as a transdermal patch
(Butrans) and in a parenteral formulation (Buprenex, and
generics) for treatment of pain. A sublingual formulation
of buprenorphine and buccal and sublingual formulations
containing buprenorphine and the opioid antagonist
naloxone are approved for use as alternatives to
methadone for treatment of opioid dependence.